Login / Signup

FOXL2C134W : much ado about something!†.

Peter J FullerTrang NguyenMaria AlexiadisSimon Chu
Published in: The Journal of pathology (2021)
Recent studies have suggested that the unique FOXL2C134W mutation, which is pathognomonic for adult granulosa cell tumours of the ovary, is a tumour suppressor gene. In a recent issue of The Journal of Pathology, a detailed study by Pilsworth et al seeks to rebut the proposition that the FOXL2C134W mutation, which uniquely characterises adult granulosa cell tumours of the ovary, leads to reduced transcript levels with the implication that FOXL2 is a tumour suppressor gene. The study provides compelling evidence that both wild-type and mutant FOXL2 transcripts and protein are expressed at equivalent levels. In the context of other recent studies, one is drawn to the conclusion that FOXL2C134W is a gain-of-function mutation whose impact is mediated through enhanced interactions with the SMAD transcription factor complex. © 2021 The Pathological Society of Great Britain and Ireland.
Keyphrases
  • wild type
  • transcription factor
  • single cell
  • cell therapy
  • copy number
  • stem cells
  • polycystic ovary syndrome
  • gene expression
  • type diabetes
  • adipose tissue
  • dna binding